ChanEx gene therapy - Oxford Biomedica
Latest Information Update: 13 Aug 2003
At a glance
- Originator Oxford BioMedica
- Developer Nonindustrial source; Oxford BioMedica
- Class Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 13 Aug 2003 Discontinued - Preclinical for Cystic fibrosis in United Kingdom (unspecified route)
- 12 Feb 1999 New profile
- 12 Feb 1999 Preclinical development for Cystic fibrosis in United Kingdom (Unknown route)